London, UK (PRWEB) February 16, 2015
Opioids are presently one of the most potent analgesics available for clinical use, with prescriptions surging by 50% over the decade for chronic, noncancer pain. However, with the rate of opioid prescription rising, there is a corresponding hike in opioid overdose deaths, misuse and addiction. On the back of abusive potential of opioid medications reported across the U.S., the FDA has recently drafted guidance for assessing and labeling of opioids formulations on the basis of their ability to diminish its abusive potential. In spite of the process being in its infancy, a number of specialty companies have ventured into the development of abuse deterrent formulations to cash in on in the short run.
Worldwide, pain is one of the key therapy areas and is the major cause of disability in the United States, affecting more than cancer, diabetes and heart disease combined. The size of the market for pain management drugs was estimated at more than USD 50 billion as of 2013 and is projected to increase at 10%. The recent patent expiry of Cymbalta and Lyrica (valid till December 30, 2018) is set to significantly impact the total pain market size in the near term. However, a number of pipeline molecules are emerging to bridge this gap.
Comprehensive market research report “Moderate to Severe Pain: Novel Abuse Deterrent Formulation Technologies and Emergence of Novel Mechanisms in the Management of Pain” elaborated by MP Advisors has been recently published at MarketPublishers.com.
Title: Moderate to Severe Pain: Novel Abuse Deterrent Formulation Technologies and Emergence of Novel Mechanisms in the Management of Pain
Published: January, 2015
Price: US$ 3,000.00
The study examines the pain management market. It includes a detailed classification of pain (type and intensity), examines the current approach to the treatment of chronic pain, analyses the pain market size and actual therapeutic options, evaluates the unmet medical needs and key market opportunities, reviews marketed drugs for various types of pain, discusses benefits and limitations of non-opioid drugs and gives an overview of marketed drugs, points out the necessity for non-opiate pain treatments. The report looks into the FDA’s schedule for controlled substances, and also reviews the FDA’s guidelines for the development of abuse-deterrent formulations (ADFs). A discussion of abuse deterrent technology platforms utilised in marketed drugs and pipeline is provided in the study, and is a pipeline analysis of new technologies and novel mechanisms in the management of pain. The research report also limelights therapies for neuropathic pain in late clinical development stages. Additionally, the study analyses the competitive scene as well as profiles the top market players.
- True knowledge of the global pain management market performance.
- Granular review of the unmet needs and brightest opportunities in the market space.
- Essential information on the products marketed at present.
- Investigation of the most recent pain drug launches.
- Comprehensive assessment of the competitive landscape.
- In-depth analysis of the leading market players’ performance, covering detailed profiles, including reviews of the offerings.
- Shrewd look at drug clinical milestones.
- Deep insight into key market trends, developments and important industry issues.
More comprehensive studies by the publisher can be found at MP Advisors page.